)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
IDEAYA Biosciences (IDYA) investor relations material
IDEAYA Biosciences Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary3 Dec, 2025
Pipeline and clinical development updates
Lead program Darovasertib is nearing a key randomized median PFS readout for metastatic uveal melanoma, with potential accelerated approval filing in the U.S. expected by year-end or early next year.
Full enrollment for the median OS component in the registrational study is nearly complete, targeting over 450 patients.
Additional registrational trials for Darovasertib include a phase 3 neoadjuvant trial (sites activated, patients screening) and a phase 3 adjuvant trial launching in the first half of next year.
Breakthrough therapy designation was received for the neoadjuvant indication based on strong eye preservation data.
Multiple clinical assets in the MTAP pathway are advancing, including phase 2 MAT2A inhibitor, phase 1 PRMT5 inhibitor, and a new program targeting CDKN2A co-alteration.
Clinical data and patient impact
In uveal melanoma, there are no approved systemic therapies for neoadjuvant or adjuvant settings, and most metastatic patients lack approved options.
Neoadjuvant trial aims to exceed a 10% eye preservation rate; recent data show the majority of patients preserving their eyes, supporting breakthrough designation.
Plaque therapy cohort targets a 20% or greater improvement in vision (15-letter BCVA test) versus control, with secondary endpoints for event-free survival.
Neoadjuvant treatment showed a mean 14-letter vision gain pre-procedure, potentially improving outcomes post-radiotherapy.
ADC and targeted therapy programs
DLL3 topo ADC in small cell lung cancer showed a 70% confirmed response rate at 2.4 mg/kg and a PFS of 6.7 months, with grade 3+ AEs under 20%.
Dose intensity is critical for efficacy; discontinuations and dose interruptions were infrequent.
Plans to develop DLL3 ADC in both small cell lung cancer and neuroendocrine tumors, with additional data updates expected next year.
Resistance to DLL3 therapies is not expected to arise from antigen downregulation due to its link to ASCL1; distinct binding epitopes may allow for combination strategies.
Darovasertib PFS: What's the commercialization path
DLL3 ADC: Resistance mechanisms and differentiation
PARG: How amplify topo ADC durability
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next IDEAYA Biosciences earnings date
Q4 202513 Feb, 2026
Next IDEAYA Biosciences earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
IDEAYA Biosciences Inc. is a clinical-stage biotechnology firm primarily engaged in the discovery and development of precision medicine therapeutics for cancer patients. The company's research focuses on synthetic lethality, an innovative class of precision medicine targets, aiming to produce therapeutics that are first-in-class and/or best-in-class. IDEAYA Biosciences leverages molecular diagnostics to select patient populations for its targeted therapies, emphasizing an integrated approach to the discovery and development of biomarkers and therapeutics. This approach spans early discovery through clinical development, targeting unmet needs in cancer treatment. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage